Despite encouraging clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from pharmacy benefit managers. These companies are frequently erecting barriers to reimbursement, like high cost restrictions and prior authorization that limit read more user availab